Myriad Genetics (MYGN) Stock Forecast, Price Target & Predictions
MYGN Stock Forecast
Myriad Genetics stock forecast is as follows: an average price target of $30.20 (represents a 140.83% upside from MYGN’s last price of $12.54) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.
MYGN Price Target
The average price target for Myriad Genetics (MYGN) is $30.20 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $21.00. This represents a potential 140.83% upside from MYGN's last price of $12.54.
MYGN Analyst Ratings
According to 13 Wall Street analysts, Myriad Genetics's rating consensus is 'Hold'. The analyst rating breakdown for MYGN stock is 0 'Strong Buy' (0.00%), 3 'Buy' (23.08%), 10 'Hold' (76.92%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Myriad Genetics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 09, 2024 | Puneet Souda | Leerink Partners | $21.00 | $15.15 | 38.61% | 67.46% |
| Oct 14, 2024 | Sung Ji Nam | Scotiabank | $34.00 | $24.67 | 37.82% | 171.13% |
| Sep 19, 2024 | Tejas Savant | Morgan Stanley | $32.00 | $28.47 | 12.40% | 155.18% |
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $35.00 | $27.50 | 27.27% | 179.11% |
| Aug 07, 2024 | Subbu Nambi | Guggenheim | $29.00 | $25.96 | 11.71% | 131.26% |
| Jun 26, 2024 | Sung Ji Nam | Scotiabank | $29.00 | $24.62 | 17.79% | 131.26% |
| May 13, 2024 | Jon Peterson | Piper Sandler | $28.00 | $25.07 | 11.69% | 123.29% |
| Dec 21, 2023 | David Westenberg | Piper Sandler | $23.00 | $20.49 | 12.25% | 83.41% |
| Oct 05, 2022 | Mason Carrico | Stephens | $22.00 | $20.82 | 5.67% | 75.44% |
| Apr 19, 2022 | Goldman Sachs | $23.00 | $23.03 | -0.13% | 83.41% |
The latest Myriad Genetics stock forecast, released on Dec 09, 2024 by Puneet Souda from Leerink Partners, set a price target of $21.00, which represents a 38.61% increase from the stock price at the time of the forecast ($15.15), and a 67.46% increase from MYGN last price ($12.54).
Myriad Genetics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 7 |
| Avg Price Target | - | $21.00 | $29.71 |
| Last Closing Price | $12.54 | $12.54 | $12.54 |
| Upside/Downside | -100.00% | 67.46% | 136.92% |
In the current month, the average price target of Myriad Genetics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Myriad Genetics's last price of $12.54. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 09, 2024 | Leerink Partners | Outperform | Market Perform | Downgrade |
| Oct 14, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Sep 19, 2024 | Morgan Stanley | Equal-Weight | Initialise | |
| Aug 27, 2024 | Wells Fargo | Overweight | Initialise | |
| Aug 13, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Aug 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 07, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Aug 07, 2024 | Guggenheim | Buy | Buy | Hold |
| Jun 26, 2024 | Scotiabank | Outperform | Sector Outperform | Initialise |
| Jun 26, 2024 | Scotiabank | Outperform | Initialise | |
| Jun 03, 2024 | Jefferies | Underperform | Downgrade | |
| May 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 08, 2024 | Leerink Partners | Outperform | Upgrade | |
| May 23, 2023 | SVB Leerink | Market Perform | Downgrade | |
| May 23, 2023 | Citigroup | Neutral | Downgrade | |
| May 23, 2023 | Keefe, Bruyette & Woods | Market Perform | Upgrade | |
| May 23, 2023 | Goldman Sachs | Buy | Upgrade | |
| May 23, 2023 | EF Hutton | Hold | Downgrade | |
| May 23, 2023 | Credit Suisse | Neutral | Downgrade | |
| Oct 06, 2022 | Stephens | Equal-Weight | Initialise |
Myriad Genetics's last stock rating was published by Leerink Partners on Dec 09, 2024. The company Downgrade its MYGN rating from "Outperform" to "Market Perform".
Myriad Genetics Financial Forecast
Myriad Genetics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $191.90M | - | $181.20M | $177.80M | $156.40M | $179.30M | $164.90M | $160.80M | $167.30M | $189.40M | $173.10M | $154.60M | $145.20M | $93.20M | $164.00M | $195.10M | $186.30M |
| Avg Forecast | $246.09M | $237.95M | $238.94M | $230.71M | $224.60M | $218.83M | $219.33M | $211.60M | $212.17M | $210.76M | $206.44M | $193.51M | $194.80M | $182.32M | $187.16M | $171.49M | $169.47M | $170.07M | $170.96M | $156.67M | $162.96M | $165.04M | $162.54M | $154.42M | $93.89M | $167.38M | $209.66M | $202.32M | $221.64M | $217.77M |
| High Forecast | $254.00M | $245.60M | $246.61M | $238.13M | $231.81M | $225.86M | $226.38M | $219.36M | $212.76M | $210.85M | $206.44M | $193.63M | $195.47M | $183.87M | $193.17M | $177.00M | $174.02M | $170.07M | $170.96M | $156.67M | $162.96M | $165.04M | $162.54M | $154.42M | $93.89M | $167.38M | $209.66M | $202.32M | $221.64M | $217.77M |
| Low Forecast | $240.15M | $232.21M | $233.17M | $225.14M | $219.17M | $213.55M | $214.04M | $204.84M | $211.58M | $210.66M | $206.44M | $193.38M | $193.36M | $180.77M | $182.64M | $167.35M | $165.53M | $170.07M | $170.96M | $156.67M | $162.96M | $165.04M | $162.54M | $154.42M | $93.89M | $167.38M | $209.66M | $202.32M | $221.64M | $217.77M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | - | 1.06% | 1.05% | 0.92% | 1.05% | 1.05% | 0.99% | 1.01% | 1.17% | 1.12% | 1.65% | 0.87% | 0.44% | 0.81% | 0.88% | 0.86% |
Myriad Genetics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $194.80M, with a low forecast of $193.36M, and a high forecast of $195.47M. MYGN's average Quarter revenue forecast represents a 1.51% increase compared to the company's last Quarter revenue of $191.90M (Sep 23).
Myriad Genetics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-46.10M | $-297.20M | $-32.70M | $-31.30M | $-30.30M | $-4.40M | $-1.80M | $-29.70M | $55.10M | $15.10M | $-28.20M | $-34.70M | $-23.10M | $-37.60M | $-110.90M | $9.30M | $-1.20M |
| Avg Forecast | $-22.00M | $-21.27M | $-21.36M | $-20.63M | $-20.08M | $-19.56M | $-19.61M | $-18.92M | $-18.97M | $-18.84M | $-18.45M | $-21.39M | $-17.41M | $-16.30M | $-16.73M | $-19.45M | $-32.67M | $-3.36M | $-3.38M | $-17.68M | $-3.22M | $-3.26M | $-3.21M | $-39.88M | $-1.85M | $-3.31M | $-4.14M | $-998.10M | $-4.38M | $-4.30M |
| High Forecast | $-21.47M | $-20.76M | $-20.84M | $-20.13M | $-19.59M | $-19.09M | $-19.13M | $-18.31M | $-18.91M | $-18.83M | $-18.45M | $-17.11M | $-17.29M | $-16.16M | $-16.33M | $-15.56M | $-26.14M | $-3.36M | $-3.38M | $-14.14M | $-3.22M | $-3.26M | $-3.21M | $-31.91M | $-1.85M | $-3.31M | $-4.14M | $-798.48M | $-4.38M | $-4.30M |
| Low Forecast | $-22.71M | $-21.96M | $-22.05M | $-21.29M | $-20.72M | $-20.19M | $-20.24M | $-19.61M | $-19.02M | $-18.85M | $-18.45M | $-25.67M | $-17.47M | $-16.44M | $-17.27M | $-23.34M | $-39.20M | $-3.36M | $-3.38M | $-21.21M | $-3.22M | $-3.26M | $-3.21M | $-47.86M | $-1.85M | $-3.31M | $-4.14M | $-1.20B | $-4.38M | $-4.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.83% | 17.76% | 1.68% | 0.96% | 9.02% | 1.30% | 0.10% | 9.23% | -16.91% | -4.70% | 0.71% | 18.71% | 6.99% | 9.08% | 0.11% | -2.12% | 0.28% |
5 analysts predict MYGN's average Quarter EBITDA for Dec 21 to be $-3.22M, with a high of $-3.22M and a low of $-3.22M. This is -105.84% lower than Myriad Genetics's previous annual EBITDA (Sep 21) of $55.10M.
Myriad Genetics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-61.30M | $-116.10M | $-54.70M | $-42.30M | $-35.10M | $-14.10M | $-20.50M | $-7.60M | $24.60M | $-4.70M | $-39.50M | $-44.20M | $-15.20M | $-55.40M | $-115.20M | $-8.30M | $-20.60M |
| Avg Forecast | $9.27M | $7.44M | $7.93M | $5.98M | $4.16M | $2.46M | $918.45K | $-650.12K | $2.54M | $1.70M | $-1.06M | $-35.08M | $1.29M | $-6.87M | $-7.37M | $-31.89M | $-8.36M | $-3.28M | $2.05M | $-28.99M | $-1.94M | $-1.46M | $-8.28M | $-55.86M | $-38.13M | $614.25K | $25.08M | $-1.04B | $38.19M | $35.51M |
| High Forecast | $9.66M | $7.76M | $8.26M | $6.23M | $4.33M | $2.56M | $956.81K | $2.60M | $4.23M | $1.74M | $-1.03M | $-28.07M | $1.34M | $-6.65M | $-7.14M | $-25.51M | $-6.69M | $-3.28M | $2.05M | $-23.19M | $-1.94M | $-1.46M | $-8.28M | $-44.69M | $-38.13M | $614.25K | $25.08M | $-829.44M | $38.19M | $35.51M |
| Low Forecast | $8.98M | $7.21M | $7.68M | $5.80M | $4.03M | $2.38M | $889.62K | $-3.25M | $1.69M | $1.67M | $-1.10M | $-42.10M | $643.89K | $-7.15M | $-7.68M | $-38.27M | $-10.03M | $-3.28M | $2.05M | $-34.79M | $-1.94M | $-1.46M | $-8.28M | $-67.04M | $-38.13M | $614.25K | $25.08M | $-1.24B | $38.19M | $35.51M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.93% | 15.75% | 1.72% | 5.06% | 10.71% | -6.89% | 0.71% | 3.91% | -16.90% | 0.57% | 0.71% | 1.16% | -24.75% | -2.21% | 0.11% | -0.22% | -0.58% |
Myriad Genetics's average Quarter net income forecast for Dec 21 is $-1.94M, with a range of $-1.94M to $-1.94M. MYGN's average Quarter net income forecast represents a -107.89% decrease compared to the company's last Quarter net income of $24.60M (Sep 21).
Myriad Genetics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $170.40M | $140.70M | $151.70M | $146.50M | $130.50M | $127.10M | $110.60M | $139.30M | $180.20M | $134.80M | $145.50M | $132.90M | $124.10M | $107.40M | $132.90M | $135.60M | $135.50M |
| Avg Forecast | $193.89M | $187.48M | $188.26M | $181.78M | $176.96M | $172.42M | $172.81M | $166.72M | $167.17M | $166.05M | $162.65M | $189.27M | $153.48M | $143.65M | $147.46M | $135.12M | $85.03M | $130.32M | $131.00M | $156.42M | $124.88M | $126.47M | $124.56M | $118.33M | $71.95M | $128.27M | $160.67M | $155.03M | $169.84M | $166.88M |
| High Forecast | $200.12M | $193.51M | $194.30M | $187.62M | $182.64M | $177.95M | $178.36M | $172.83M | $167.63M | $166.13M | $162.65M | $227.12M | $154.01M | $144.87M | $152.20M | $139.46M | $102.04M | $130.32M | $131.00M | $187.70M | $124.88M | $126.47M | $124.56M | $118.33M | $71.95M | $128.27M | $160.67M | $155.03M | $169.84M | $166.88M |
| Low Forecast | $189.21M | $182.95M | $183.71M | $177.39M | $172.68M | $168.25M | $168.64M | $161.39M | $166.70M | $165.98M | $162.65M | $151.41M | $152.34M | $142.43M | $143.90M | $131.86M | $68.02M | $130.32M | $131.00M | $125.14M | $124.88M | $126.47M | $124.56M | $118.33M | $71.95M | $128.27M | $160.67M | $155.03M | $169.84M | $166.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.19% | 0.95% | 1.12% | 1.72% | 1.00% | 0.97% | 0.71% | 1.12% | 1.42% | 1.08% | 1.23% | 1.85% | 0.97% | 0.67% | 0.86% | 0.80% | 0.81% |
Myriad Genetics's average Quarter SG&A projection for Dec 23 is $153.48M, based on 8 Wall Street analysts, with a range of $152.34M to $154.01M. The forecast indicates a -9.93% fall compared to MYGN last annual SG&A of $170.40M (Sep 23).
Myriad Genetics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.75 | $-1.42 | $-0.67 | $-0.52 | $-0.43 | $-0.18 | $-0.26 | $-0.10 | $0.31 | $-0.06 | $-0.52 | $-0.59 | $-0.20 | $-0.74 | $-1.55 | $-0.11 | $-0.28 |
| Avg Forecast | $0.10 | $0.08 | $0.09 | $0.07 | $0.05 | $0.03 | $0.01 | $-0.01 | $0.03 | $0.02 | $-0.01 | $-0.10 | $0.01 | $-0.08 | $-0.08 | $-0.19 | $-0.16 | $-0.04 | $0.03 | $-0.08 | $-0.02 | $-0.02 | $-0.10 | $-0.15 | $-0.47 | $0.01 | $0.31 | $0.31 | $0.47 | $0.43 |
| High Forecast | $0.11 | $0.09 | $0.09 | $0.07 | $0.05 | $0.03 | $0.01 | $0.03 | $0.05 | $0.02 | $-0.01 | $-0.10 | $0.01 | $-0.07 | $-0.08 | $-0.19 | $-0.16 | $-0.04 | $0.03 | $-0.08 | $-0.02 | $-0.02 | $-0.10 | $-0.15 | $-0.47 | $0.01 | $0.31 | $0.31 | $0.47 | $0.43 |
| Low Forecast | $0.10 | $0.08 | $0.08 | $0.06 | $0.04 | $0.03 | $0.01 | $-0.04 | $0.02 | $0.02 | $-0.01 | $-0.11 | $0.01 | $-0.08 | $-0.08 | $-0.20 | $-0.17 | $-0.04 | $0.03 | $-0.08 | $-0.02 | $-0.02 | $-0.10 | $-0.15 | $-0.47 | $0.01 | $0.31 | $0.31 | $0.47 | $0.43 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.93% | 17.51% | 3.47% | 3.18% | 10.75% | -7.20% | 3.13% | 4.01% | -17.44% | 0.59% | 3.44% | 1.27% | -26.67% | -2.42% | -4.93% | -0.24% | -0.65% |
According to 5 Wall Street analysts, Myriad Genetics's projected average Quarter EPS for Dec 21 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -107.65% decrease compared to MYGN previous annual EPS of $0.31 (Sep 21).
Myriad Genetics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics | $2.36 | $6.00 | 154.24% | Buy |
| MYGN | Myriad Genetics | $12.54 | $30.20 | 140.83% | Hold |
| CDNA | CareDx | $22.56 | $37.50 | 66.22% | Buy |
| NEOG | Neogen | $11.50 | $17.50 | 52.17% | Buy |
| CSTL | Castle Biosciences | $27.49 | $40.50 | 47.33% | Buy |
| PSNL | Personalis | $5.01 | $7.38 | 47.31% | Buy |
| EXAS | Exact Sciences | $54.89 | $77.00 | 40.28% | Buy |
| RDNT | RadNet | $67.17 | $89.00 | 32.50% | Buy |
| SHC | Sotera Health | $13.68 | $16.00 | 16.96% | Buy |
| ILMN | Illumina | $131.72 | $150.00 | 13.88% | Buy |
| QGEN | Qiagen | $43.77 | $49.00 | 11.95% | Buy |
| MEDP | Medpace | $343.02 | $369.67 | 7.77% | Hold |
| TWST | Twist Bioscience | $49.52 | $46.00 | -7.11% | Buy |
| NTRA | Natera | $168.22 | $154.80 | -7.98% | Buy |
| GH | Guardant Health | $47.65 | $39.00 | -18.15% | Buy |